arly Central Nervous System Complications after educed-Intensity Stem Cell Transplantation

To investigate clinical characteristics of early central nervous system (CNS) complications after reducedintensity stem cell transplantation (RIST), we reviewed the medical records of 232 patients who had undergone RIST for hematologic diseases at our institutions between September 1999 and June 2003. All patients had received purine analog–based preparative regimens. Stem cell sources comprised granulocyte colony-stimulating factor–mobilized blood from HLA-identical or 1 locus–mismatched related donors (n 151), unrelated bone marrow (n 44), or unrelated cord blood (n 37). Graft-versus-host disease prophylaxis incorporated cyclosporine with or without methotrexate. Diagnosis of CNS complications was based on clinical, radiologic, and microbiological findings. CNS complications occurred in 18 patients (7.8%), with a median onset of 22 days, and were infectious (n 1), metabolic (n 15), or cerebrovascular (n 2). Symptoms included seizures (n 7), visual disturbance (n 2), headache (n 8), nausea (n 8), vomiting (n 6), impaired consciousness (n 16), and hemiparesis (n 3). Complications improved promptly in 10 patients, and 8 patients died without improvement within 30 days. Multivariate analysis with logistic regression identified umbilical cord blood transplantation as a significant risk factor for early CNS complications (odds ratio, 14.5; 95% confidence interval, 3.7-56.9; P < .0001). CNS complications are a significant problem after RIST, particularly with umbilical cord blood. Limbic encephalopathy is an unrecognized subtype of neurotoxicity after umbilical cord blood transplantation. © 2004 American Society for Blood and Marrow Transplantation